SWISS DAYBOOK: SGS, Barry Callebaut, Roche, Sonova, Transocean

SGS SA (SGSN) reported net income of 534 million Swiss francs, in line with analyst estimates, and proposed a total dividend of 65 francs a share.

The company also said it may buy back as much as 250 million francs of shares.

EQUITIES: *Barry Callebaut (BARN) AG said sales volume rose 2.6 percent in the three months ending Nov. 30 2011 *Combining GlaxoSmithKline Plc’s Tykerb drug with Roche Holding AG’s Herceptin to treat breast cancer was almost twice as effective as single-drug therapy, according to researchers in a 23-country clinical trial. *Sonova Holding AG (SOON) shareholder Andy Rihs plans to reduce his stake in the company to 7-8 percent from 9 percent *Chevron Corp. ordered three new shallow-water drilling rigs from Transocean Ltd. (RIGN) for Thailand exploration projects *Galenica (GALN) AG said 2011 sales rose 2.6 percent to 3.19 billion francs *Komax (KOMN) Holding AG said full-year revenue climbed 9 percent to around 370 million francs *Martin Schaufelberger was named new chief executive of Coltene (CLTN) Holding AG *Aryzta AG (ARYN) applied to the Irish Stock Exchange for the listing of 4.2 million registered shares *Implenia AG (IMPN) won an order to build the tallest building in Zug, Switzerland

ECONOMY: *Switzerland sells three-month bills today

MARKETS: *The benchmark SMI gained 0.6 percent to 6,031.24 *The SPI increased 0.5 percent to 5,440.51 *The Stoxx Europe 600 Index advanced 0.8 percent to 251.12 *The MSCI Asia-Pacific Index rose 1.7 percent by 7:36 a.m. Swiss time *Euro-franc traded at 1.2101 at 7:37 a.m. Zurich time

To contact the reporter on this story: Klaus Wille in Zurich at kwille@bloomberg.net

To contact the editor responsible for this story: Craig Stirling at cstirling1@bloomberg.net